Long-term testicular cancer survivors at high risk for neurological side effects
Key points
- Marianne Brydøy, M.D., of the Department of Oncology, Haukeland University Hospital, in Bergen, Norway, and colleagues conducted a cross-sectional study to assess the prevalence of these known side effects among long-term testicular cancer survivors in Norway according to the treatment they had received.
- Researchers invited 1,814 men who were treated for unilateral testicular cancer during 1980-1994 to participate in a national multicenter follow-up survey conducted during 1998-2002.
- The researchers found that at 4-21 years after the initiation of treatment for testicular cancer, men who had received any chemotherapy had statistically significantly higher odds for increasing severity of all assessed symptoms compared with men not treated with chemotherapy.
- "A major aim in the treatment of testicular cancer is to minimize toxic effects without compromising the high cure rate," the authors write.
Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy had more severe side effects, including neurological side effects and Raynaud-like phenomena, than men who were not treated with chemotherapy, according to a new study published online November 25 in the Journal of the National Cancer Institute.
Marianne Brydøy, M.D., of the Department of Oncology, Haukeland University Hospital, in Bergen, Norway, and colleagues conducted a cross-sectional study to assess the prevalence of these known side effects among long-term testicular cancer survivors in Norway according to the treatment they had received. Side effects include sensory neuropathy, tinnitus, hearing impairment, and Raynaud-like phenomena (discoloration of the hands or feet on exposure to cold).
Researchers invited 1,814 men who were treated for unilateral testicular cancer during 1980-1994 to participate in a national multicenter follow-up survey conducted during 1998-2002. A total of 1,409 participants, who were allocated to three groups based on cisplatin administration, were assessable in this study.
The researchers found that at 4-21 years after the initiation of treatment for testicular cancer, men who had received any chemotherapy had statistically significantly higher odds for increasing severity of all assessed symptoms compared with men not treated with chemotherapy. Treated men also had more hearing impairment, as measured by audiometry, particularly those who had received dose-intensive chemotherapy.
"A major aim in the treatment of testicular cancer is to minimize toxic effects without compromising the high cure rate," the authors write. "Our data favor the use of chemotherapy regimens that contain 20 mg/m2 cisplatin per day to limit ototoxicity."
###
Contact: Marianne Brydøy, [email protected], +47 55 97 35 96/ +47 55 97 20 10
Note to Reporters: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
Visit JNCI online at http://jnci.oxfordjournals.org and the JNCI press room at http://www.oxfordjournals.org/our_journals/jnci/press_room.html
For the latest cancer news and studies, follow us on Twitter @JNCI_Now
Contact: Steve Graff
[email protected]
301-841-1285
Journal of the National Cancer Institute
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsLong-term cannabis use raises risk of lung cancer
Cannabis increases the risk of lung cancer and may cause 5 per cent of cases of the disease in people aged 55 and under, according to a new study being published later this year. Researchers have found a five-fold…
3 April 2007
NewsNaturally produced protein that helps protect us from cancer may also determine how long we live
The reason why people are at greater risk of developing cancer as they get older may be explained by research published today. Scientists have discovered that a naturally produced protein that helps protect us from…
3 June 2006
NewsNo long-term cancer risk seen from breast implants
Results of a study that followed women up to 30 years adds to evidence that silicone breast implants do not boost cancer risk. The study, of nearly 2,800 Danish women who got breast implants between 1973 and 1995, found…
